Multicentric reticulohistiocytosis (MRH) is a rare systemic disorder belonging to non-Langerhans cell histiocytosis, which is characterized by severe destructive arthritis and multiple skin nodules. It is thought that proinflammatory cytokines, such as tumour necrosis factor-α (TNF-α), interleukin 1β (IL-1β), IL-6 and IL-12 secreted by monocytes and macrophages, may be associated with the pathogenesis of skin lesions and destructive arthritis in MRH, and that the inhibition of these cytokines may be useful for therapy (1, 2). There are several case reports of successful or unsuccessful treatments using anti-TNF-α reagents, such as infliximab (3–6), etanercept (7–9) and adalimumab (10, 11). We report here a case of MRH that was resistant to combination therapy of prednisolone, methotrexate (MTX) and golimumab (another anti-TNF-α drug administrated subcutaneously every 4 weeks), but finally responded to prednisolone, MTX and adalimumab.

CASE REPORT

A 54-year-old Japanese woman visited our hospital in August 2002, presenting with multiple nodules on her hands and fingers. She had noticed nodules on her index finger in 1998, and multiple firm, pale-reddish papules and subcutaneous nodules gradually appeared on the dorsal aspect of both hands, forearms, upper arms, toes, face and scalp. She developed severe arthralgia in the fingers, wrist, shoulder and knee joints. The patient’s family and past history were unremarkable. Routine laboratory tests, including blood cell counts and C-reactive protein levels, were within the normal ranges. Antinuclear antibody and rheumatoid factor were negative. Serum matrix metalloproteinase-3 level was elevated (159.2 ng/ml, normal 17.3–59.7 ng/ml). Serum IL-6 level was within the normal limit. Histological examination of the nodules on her finger revealed multinucleated giant cells throughout the dermis, containing eosinophilic and fine granular ground-glass cytoplasm. Plane X-ray of the hands revealed progressive erosions with pencil-in-cup deformities, spur formations and subluxations of the distal and proximal interphalangeal joints and metacarpal phalangeal joints of all fingers (Fig. 1C, D). Computed tomography of the whole body and fluorodeoxyglucose-positron emission tomography (FDG-PET) scan revealed no internal malignancies. Based on these findings, a diagnosis of MRH was established. Treatment with oral prednisolone was started in October 2002 (maximum dose 30 mg/day). Since the skin and joint lesions did not improve, the prednisolone dose was tapered to 5–10 mg/day. Treatment with oral MTX (4–6 mg/week) was started in July 2006; however, the number and size of multiple nodules increased. Golimumab (50 mg), a human monoclonal antibody to TNF-α, was administered subcutaneously every 4 weeks beginning in March 2013 with continuation of prednisolone.
and MTX. Although the combination therapy was continued for 12 months, the number and size of multiple cutaneous and subcutaneous nodules on all fingers increased, arthralgia was exacerbated, and swelling of the right wrist developed (Fig. 1A, B). Magnetic resonance imaging (MRI) with short-tau inversion recovery (STIR) of the right hand revealed high signal intensities in the tendons of the flexor palmar and digital muscles (Fig. 1G). Golimumab was therefore replaced with adalimumab (40 mg every other week) with continuation of prednisolone (6 mg/day) and MTX (6 mg/week) in February 2014. Twelve weeks later, the multiple skin lesions gradually improved. Ten months after starting adalimumab therapy, the number and size of multiple nodules in the fingers decreased significantly, and the swelling of the right wrist and severe pain disappeared (Fig. 1E, F). In addition, the high signal intensities in the tendons of the flexor palmar and digital muscles, previously observed on MRI with STIR, in the right hand disappeared (Fig. 1H). Since the skin lesions have not completely remitted, we plan to continue the present combination therapy.

DISCUSSION

The pathogenesis of MRH remains unknown. Immunohistochemical analyses demonstrated the presence of histiocytes of a monocytic-macrophage origin and high levels of expression of proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, in local lesions (1). In addition, Bennässar et al. (2) reported elevated serum TNF-α, IL-1β and IL-6 levels were in a patient with MRH, that decreased after treatment with prednisolone and MTX, along with an improvement in symptoms. These findings suggest that the production of these proinflammatory cytokines by histiocytes might be involved in the pathogenesis of MRH.

Various treatments have been reported, including non-steroidal anti-inflammatory agents, prednisolone, isoniazid, MTX, cyclosporine, cyclophosphamide, alendronate and minocycline, alone or in combination (3, 12). In addition, sun-protective clothing and sunscreens are recommended to prevent the development of skin eruptions, via the ultraviolet light-induced Köbner phenomenon (13). To the best of our knowledge, there are currently 10 reported cases of MRH that have been treated with anti-TNF agents, such as infliximab (3–6), etanercept (7–9) and adalimumab (10, 11), but the clinical outcome is controversial. Shannon et al. (10) reported an improvement in joint lesions after combination therapy with adalimumab (40 mg every other week), prednisolone, cyclosporine and mycophenolate mofetil. Yeter and Arkfeld (11) reported that skin lesions were improved by treatment with MTX and etanercept, but joint lesions were not; however switching to adalimumab in place of etanercept and adding minocycline resulted in a sustained improvement in both the skin and joint symptoms. In the current case, replacement of golimumab with adalimumab (in combination with prednisolone and MTX) resulted in a significant improvement in both skin and joint symptoms, suggesting that adalimumab could be a treatment of choice for MRH. Since both golimumab and adalimumab are human monoclonal antibodies to TNF-α, the reason for their discrepant efficacy in MRH is unknown.

The authors declare no conflicts of interest.

REFERENCES